LABORATORY PRODUCTS AND SERVICES
The Orbisint CPS 11 pH electrode operates fermentation processes with control of pH values...
LABORATORY NEWS
-
Guardant Health Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS
Guardant Health, Inc., a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.
- Predicta Biosciences And CIMA LAB Diagnostics Announce Agreement To Advance Ultrasensitive Blood-Based Diagnostics For Multiple Myeloma And Other Hematological Malignancies
- Watchmaker To Unveil New Technologies Addressing NGS Workflow Bottlenecks And Sequencing Accuracy Challenges At ESHG 2026
- Personalis Enables Global Biopharma Support With CE-IVD Marked Specimen Collection Kits
- Scispot Raises $8M Series A To Help Life Sciences Labs Move Faster
ARCHIVED NEWSLETTER
- 05.26.26 -- Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
- 04.21.26 -- Proteomics Tools: A Resurrection
- 04.07.26 -- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- 02.24.26 -- Rethinking Disease Modification Through Targeted Immunotherapy
- 02.10.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?